Help improve the information
Suggest a correction, missing detail, or peptide addition by .
Not FDA approved
This peptide is not FDA approved for human use, and because peptides are often incompletely studied you should not use or self-experiment with it outside qualified medical supervision.
Overview
Adipotide, also referred to as Prohibitin-TP01, is an experimental adipose-vasculature-targeting peptidomimetic built from the white-fat homing motif CKGGRAKDC linked to the pro-apoptotic cargo D(KLAKLAK)2. The reviewed source set supports real preclinical obesity research in mice and obese monkeys, plus an official early human trial record on ClinicalTrials.
gov, but it does not support any established human treatment protocol or FDA-approved use. The main practical caution carried through the better-known monkey study is renal proximal-tubule toxicity that appeared dose-related and reversible after discontinuation.
Reported benefits
- Direct preclinical obesity research exists in mice and obese monkeys.
- Mechanism is targeted to adipose-tissue vasculature rather than appetite signaling.
- Monkey data showed weight loss and improved insulin-resistance markers.
- Human efficacy and safety remain unestablished.
Mechanism of action
Adipotide is a chimeric peptidomimetic. The CKGGRAKDC segment homes to prohibitin-associated targets on white-adipose-tissue vasculature, and the linked D(KLAKLAK)2 cargo supports endothelial-cell apoptosis.
The intended effect is loss of blood supply to white adipose tissue, followed by reduction of fat mass. This is not the same mechanism as GLP-1 or amylin-based satiety (the feeling of fullness after eating) drugs.
Reported Use
No FDA dosing guidance
This peptide is not covered by FDA-labeled dosing guidance on this page. Peptides are often investigational or incompletely studied. Do not self-experiment; use only with a doctor or qualified clinician.
Typical dose
No established human dosing protocol was identified; monkey research used about 0.43 mg/kg subcutaneously once daily for 28 days
Frequency
Not established for humans
Injection sites
Monkey studies used subcutaneous dosing, but that should not be repackaged as a consumer-use protocol
Best timing
Not established
Effects timeline
Weight and fat-mass change were observed over 2-4 weeks in monkey studies
Storage
Do not treat generic peptide-vial storage instructions as validated Adipotide protocol
Cycle length
Not established for humans
Break between
Not established
Loading viewer
Preparing 3D peptide scene
Quick Signals
At A Glance
A faster read on evidence, focus, structure, and status.
Evidence
Emerging human evidence
Direct animal literature exists, including mouse proof-of-concept and obese-monkey efficacy and safety work, plus an of…
5 indexed studiesCurrent level
Mixed human
Scale: low evidence to established use
Status
Regulatory and sport context
Safety
Side Effects And Safety
Switch between common side-effect notes and stop criteria to keep safety context visible.
Key cautions
- No established human safety program was identified.
- Monkey studies reported dose-related and reversible proximal-tubule renal changes, making kidney toxicity the main practical caution.
- Renal-function changes mean dehydration, volume depletion, and other kidney stressors are especially concerning.
- Injection-site and systemic tolerability remain incompletely characterized in humans.
- Marketing this compound as a normal weight-loss peptide understates the toxicity issue.
Molecule
Molecular Information
Core structure fields that help explain what kind of peptide this is and how much sequence detail is available.
Molecular weight
2557.2 Da
Chain length
25 amino-acid residues in a chimeric construct
Sequence type
Chimeric adipose-targeting peptidomimetic
Derived from
White-fat homing motif plus pro-apoptotic cargo
Amino acid sequence source string
CKGGRAKDC-GG-D(KLAKLAK)2
Mixed construct linking a targeting peptide to a mitochondria-disrupting apoptotic motif
Context
Important Context
The main context that changes how confidently this peptide should be interpreted.
Research status
Direct animal literature exists, including mouse proof-of-concept and obese-monkey efficacy and safety work, plus an official early human trial record. The reviewed source set did not identify an established human efficacy or safety program.
Regulatory and sport status
FDA review shows it is not FDA approved. based on reviewed openFDA query. Sport review: likely S0 prohibited; athlete-specific review advised.
Route Notes
Route-Specific Notes
Only shown when the source material adds route-specific details beyond the quick-start guide.
Injectable
- Administration: No source-backed human injectable administration protocol was identified.
- Absorption: No direct human pharmacokinetic program was identified.
- Cycle: Not established
- Additional: Monkey subcutaneous dosing should not be repackaged as validated human-use guidance.
Compare
How Well Documented Is It?
A quick five-point snapshot of how visible and well-documented this peptide is. Higher values mean more coverage or clearer status in that area, not better medical performance.
Research
How much published research coverage this peptide has in the linked sources, with an approval-context floor for clearly established drug products.
Source: PubMed
Regulatory
How clearly the approval or regulatory status is documented for this entry.
Source: openFDA drugsfda API
Sport
How clearly sports or competition status is documented in the linked review sources.
Source: WADA Prohibited List
Breadth
How broadly this peptide appears across discussion topics and use-case groupings in the catalog.
Source: Curated site taxonomy
Sequence
How much structure or residue-sequence detail is available for this entry.
Source: Catalog seed
Protocols
Research Protocols
Common protocol-style rows shown in a consistent table layout so every peptide page is easy to compare.
| Goal | Dose | Route | Frequency |
|---|---|---|---|
| Mouse obesity proof-of-concept | Construct-specific animal dosing | Injectable in animal studies | Daily in the cited proof-of-concept work |
| Obese monkey efficacy and safety study | About 0.43 mg/kg/day | Subcutaneous | Daily for 28 days |
Research
What It Has Been Studied For
Plain-language summaries of the main health areas where this peptide shows up in the linked research.
Stacking
What People Commonly Stack It With
A plain-language view of compounds that are commonly discussed alongside this peptide in the source material.
Practical
Preparation, Quality, And Expectations
Operational checklist blocks designed for quick scanning and repeatable page structure.
How to reconstitute
- •No validated consumer reconstitution protocol was identified for exact Adipotide.
- •Do not treat generic BAC-water instructions as source-backed medical guidance.
- •Identity, concentration, and lab-grade handling should be considered unresolved unless independently documented.
Quality indicators
Good signs
- Exact construct identity is documented.
- Traceable analytical records are available.
- Claims clearly distinguish animal data from human evidence.
Avoid
- Human-ready dosing guidance derived directly from monkey studies.
- Weight-loss marketing that minimizes renal toxicity concerns.
- Vague construct identity or unclear formulation.
- Claims of sports permissibility.
What to expect
Body-weight and white-fat changes were observed over 2-4 weeks in monkey studies.
Kidney monitoring was central because renal effects were the main recurring safety issue.
No reliable human expectation timeline was established.
References
Research And Source List
Structured reference cards with source metadata and a direct link so users can inspect the original study/source.
PubMed search
Direct Adipotide query
Direct PubMed query used to confirm the main Adipotide literature set.
PubChem compound record
PubChem CID 163360068
Compound registry record supporting the molecular formula and molecular weight fields used for Adipotide.
Reversal of obesity by targeted ablation of adipose tissue
Foundational mouse proof-of-concept paper
Foundational mouse proof-of-concept paper identifying the white-fat homing sequence and targeted adipose-vasculature ablation strategy.
A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys
Key obese-monkey efficacy and safety paper
Key obese-monkey efficacy and safety paper, including reversible renal proximal-tubule changes.
Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium
Animal-model metabolic paper
Follow-up mechanistic metabolic paper in animal models.
Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity
Newer prohibitin-targeting peptide paper
Newer prohibitin-targeting peptide paper showing the field has moved toward next-generation constructs rather than an established Adipotide clinical program.
Adipose tissue-targeting nanomedicines for obesity pharmacotherapy
Review
Review placing prohibitin-targeting approaches into broader obesity-drug development context.
ClinicalTrials.gov study NCT01262664
Official early human study record
Official early human study record for adipotide or Prohibitin-TP01 context.
openFDA Adipotide query
FDA database query
Approval-database query used for status review; no FDA-approved Adipotide product was identified in the reviewed source set.
WADA Prohibited List
Official anti-doping reference
Official anti-doping reference for current prohibited categories.
WADA S0 page
Non-approved substances
Official WADA page for non-approved substances, relevant to Adipotide as an unapproved peptide or peptidomimetic.